From the desk of CJ Gaddy:
AACR’17(4-3-17) reveals a 2nd Mem.Sloan Wolchok Lab/PPHM study.
Both PPHM+MemSloan abstracts are for Melanoma, and the lead author for both is Dr. Taha Merghoub, Co-Dir., Ludwig Collaborative Lab at MSK...
This new one, #1651, sounds exciting: “Targeting PS in Combination with Adoptive T Cell Transfer (ACT) Eliminates Advanced Tumors without Off-Target Toxicities in a Melanoma Preclinical Model”. Awaiting 3-1-17 for Full AACR abstract.
-----
AACR’17: 4-3-17 #1651 - Session: TUMOR MICROENVIRONMENT & CHECKPOINTS tinyurl.com
MemSloan Jedd Wolchok Lab+PPHM(2nd known study - revealed by AACR’17 Abstract):
“Targeting Phosphatidylserine in Combination with Adoptive T Cell Transfer Eliminates Advanced Tumors without Off-Target Toxicities in a Melanoma Preclinical Model”
Lead author: Dr. Taha Merghoub (Co-Dir., Ludwig Collaborative Lab at MSK), Co-author Jedd Wolchok, PPHM & MSKCC scientists. ( mskcc.org )
NOTES:
“Adoptive Cell Transfer (ACT)” is the transfer of cells into a patient. The cells may have originated from the patient or from another individual. The cells are most commonly derived from the immune system, with the goal of improving immune functionality and characteristics. In cancer immunotherapy, T cells are extracted from the patient, genetically modified and cultured in vitro and returned to the same patient.
-----
**From 3-2014 Immunotherapy article: “Cancer immunotherapy, particularly adoptive cell transfer (ACT), has shown great promise in the treatment of patients with late-stage disease, including those who are refractory to std. Therapies” ncbi.nlm.nih.gov
-----
**Through the support from SEAN PARKER, Stand Up To Cancer (SU2C) and the Cancer Research Institute (CRI) formed an Immunology Research Dream Team dedicated to cancer immunology: “Immunologic Checkpoint Blockade & Adoptive Cell Transfer in Cancer Therapy.” The Immunotherapy Dream Team is focused on 2 approaches for this translational cancer research project, which will unite laboratory & clinical efforts towards the immunological treatment, control, and prevention of cancer.
The 1st is investigating blockades (by inhibitory molecules called “checkpoints”) of T lymphocytes’ inhibitory receptors, which block immune responses; and the use of antibodies to remove the checkpoints, once again allowing white blood cells called T lymphocytes to kill the cancer cells.
Second, the Immunotherapy Dream Team is pursuing multiple Adoptive Cell Transfer (ACT) approaches, which increase immunity.”
DREAM TEAM LEADERSHIP: 10 scientists, incl. MSKCC’s Jedd D. Wolchok & Michel Sadelain.
parker.org
-----
**12-12-2012: MSK Researchers Jedd Wolchok & Michel Sadelain Appointed to “Stand Up To Cancer” Immunology “Dream Team”
TWO APPROACHES TO ATTACKING CANCER:
The Immunology Dream Team will pursue 2 research techniques.
The 1st, being led by Dr. Wolchok, involves studying how a type of white blood cell called a T lymphocyte, or T cell, can kill cancer cells. Sometimes, the natural function of the T lymphocyte is blocked or not activated enough to attack cancer cells, allowing the cancer to grow. Part of the Dream Team’s focus will be to investigate ways to ensure that the T lymphocytes work properly in recognizing and killing cancer cells.
The 2nd immunotherapy approach, known as Adoptive Cell Transfer (ACT), involves removing some of a patient’s T cells, enhancing their cancer-fighting abilities and growing them in the laboratory, and then infusing the enhanced cells back into the patient. This can provide a patient with an army of immune cells specifically programmed to fight against cancer. This part of the Dream Team’s research, led by Dr. Sadelain, will investigate several ways to use ACT as a cancer therapy.
mskcc.org
JEDD's 5 AACR'17 Abstracts:
PEREGRINE (Joint Mem.Sloan Kettering Wolchok Lab & PPHM):
1. 4-2-17 #574 “Phosphatidylserine targeting antibody in combination with tumor radiation and immune checkpoint blockade promotes anti-tumor activity in mouse B16 melanoma”
2. 4-3-17 #1651 “Targeting phosphatidylserine in combination with adoptive T cell transfer eliminates advanced tumors without off-target toxicities in a melanoma preclinical model”
NON-PEREGRINE:
3.(MSK ONLY): 4-2-17 #874 Lifting the iron curtain: Imaging cellular barriers to combination chelation-immune checkpoint therapy
4.(MSK & Genocea Bio. genocea.com GNCA/$130mm MktCap) 4-2-17 #632 Genome-scale neoantigen screening using ATLAS™ prioritizes candidate antigens for immunotherapy in a NSCLC patient
5.(MSK & Cedars-Sinai/LA) 34-4-17 #4705 CTLA4 blockade with HER2-directed therapy (H) yields clinical benefit in women undergoing radiation therapy (RT) for HER2-positive (HER2+) breast cancer brain metastases (BCBM) |
